Avadel Pharmaceuticals plc (AVDL) Financials

AVDL Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 261.1 million 173.4 million
2023-09-30 203.1 million 93.0 million
2023-06-30 201.0 million 57.8 million
2023-03-31 140.7 million 178.9 million

AVDL Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -28.0 million 3.5 million
2023-09-30 -38.2 million 3.1 million
2023-06-30 -32.0 million 7.6 million
2023-03-31 -30.2 million 1.5 million

AVDL Net Income

No data available :(

AVDL Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 105.1 million - 2.6 million
2023-09-30 153.2 million - 2.8 million
2023-06-30 160.5 million - 1.3 million
2023-03-31 100.9 million - 1.5 million

AVDL Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 95.0 million
2023-09-30 89.4 million
2023-06-30 77.2 million
2023-03-31 63.9 million

AVDL Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 - 2.4 million 41.3 million -
2023-09-30 - 2.8 million 39.2 million -
2023-06-30 - 4.2 million 46.8 million -
2023-03-31 - 3.8 million 24.5 million -

AVDL Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 19.5 million 693000
2023-09-30 7.0 million 117000
2023-06-30 1.5 million 36000
2023-03-31 - 588000

AVDL

Price: $18.82

52 week price:
8.49
18.82

Earnings Per Share: -2.00 USD

P/E Ratio: -6.70

Exchange: NGM

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Volume: 237800

Ebitda: 27.2 million

Market Capitalization: 1.5 billion

Links: